Brain tumor biobanking in the precision medicine era: building a high-quality resource for translational research in neuro-oncology.

The growth of precision medicine has made access to biobanks with high-quality, well-annotated neuro-oncology biospecimens critical. Developing and maintaining neuro-oncology biobanks is best accomplished through multidisciplinary collaboration between clinicians and researchers. Balancing the needs and leveraging the skills of all stakeholders in this multidisciplinary effort is of utmost importance. Collaboration with a multidisciplinary team of clinicians, health care team members, and institutions, as well as patients and their families, is essential for access to participants in order to obtain informed consent, collect samples under strict standard operating procedures, and accurate and relevant clinical annotation. Once a neuro-oncology biobank is established, development and implementation of policies related to governance and distribution of biospecimens (both within and outside the institution) is of critical importance for sustainability. Proper implementation of a governance process helps to ensure that the biospecimens and data can be utilized in research with the largest potential benefit. New NIH and peer-reviewed journal policies related to public sharing of 'omic' data generated from stored biospecimens create new ethical challenges that must be addressed in developing informed consents, protocols, and standard operating procedures. In addition, diversification of sources of funding for the biobanks is needed for long-term sustainability.

[1]  E. Clayton,et al.  Principles of Human Subjects Protections Applied in an Opt‐Out, De‐identified Biobank , 2010, Clinical and translational science.

[2]  S. B. King,et al.  Testing an Online, Dynamic Consent Portal for Large Population Biobank Research , 2014, Public Health Genomics.

[3]  E. Gillanders,et al.  The use of biospecimens in population-based research: a review of the National Cancer Institute's Division of Cancer Control and Population Sciences grant portfolio. , 2014, Biopreservation and biobanking.

[4]  N. Cox,et al.  On sharing quantitative trait GWAS results in an era of multiple-omics data and the limits of genomic privacy. , 2012, American journal of human genetics.

[5]  D. Louis WHO classification of tumours of the central nervous system , 2007 .

[6]  J. V. van Delden,et al.  Inclusion of Residual Tissue in Biobanks: Opt-In or Opt-Out? , 2012, PLoS biology.

[7]  S. Cummings,et al.  Interactive Informed Consent: Randomized Comparison with Paper Consents , 2013, PloS one.

[8]  C. Foy,et al.  Quality assessment of biobanked nucleic acid extracts for downstream molecular analysis. , 2012, Biopreservation and biobanking.

[9]  V. Tsikitis,et al.  Surgeon leadership enables development of a colorectal cancer biorepository. , 2013, American journal of surgery.

[10]  D. Roden,et al.  Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.

[11]  P. Wen,et al.  Epidemiology of Brain Metastases , 2012, Current Oncology Reports.

[12]  Ownership and Use of Tissue Specimens for Research , 2004 .

[13]  Zhen Lin,et al.  Genomic Research and Human Subject Privacy , 2004, Science.

[14]  J. Ioannidis,et al.  Public Availability of Published Research Data in High-Impact Journals , 2011, PloS one.

[15]  G. Henderson,et al.  “That's a good question”: University researchers' views on ownership and retention of human genetic specimens , 2011, Genetics in Medicine.

[16]  K. Jang,et al.  Effects of Delay in the Snap Freezing of Colorectal Cancer Tissues on the Quality of DNA and RNA , 2010, Journal of the Korean Society of Coloproctology.

[17]  D. Roden,et al.  Biobanks and Electronic Medical Records: Enabling Cost-Effective Research , 2014, Science Translational Medicine.

[18]  W. Thasler,et al.  Biobanking for research in surgery: are surgeons in charge for advancing translational research or mere assistants in biomaterial and data preservation? , 2013, Langenbeck's Archives of Surgery.

[19]  J. Vaught,et al.  Best practices for establishing a biobank. , 2011, Methods in molecular biology.

[20]  M M Morente,et al.  TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network. , 2006, European journal of cancer.

[21]  IRB practices and policies regarding the secondary research use of biospecimens , 2015, BMC medical ethics.

[22]  Jill S Barnholtz-Sloan,et al.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. De Cecco,et al.  Impact of biospecimens handling on biomarker research in breast cancer , 2009, BMC Cancer.

[24]  S. Dry,et al.  A practical approach to clinical and research biobanking. , 2014, Methods in molecular biology.

[25]  Joakim Dillner,et al.  Ethical framework for previously collected biobank samples , 2007, Nature Biotechnology.

[26]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[27]  K. Hao,et al.  Bayesian method to predict individual SNP genotypes from gene expression data , 2012, Nature Genetics.

[28]  Paul Elliott,et al.  The UK Biobank sample handling and storage validation studies. , 2008, International journal of epidemiology.

[29]  A Plan for Academic Biobank Solvency—Leveraging Resources and Applying Business Processes to Improve Sustainability , 2015, Clinical and translational science.

[30]  P. Riegman,et al.  Standard operating procedure for the collection of fresh frozen tissue samples. , 2007, European journal of cancer.

[31]  B. Parodi,et al.  Governance of Biobanks for Cancer Research: Proposal for a Material Transfer Agreement , 2013 .

[32]  E. Clayton Informed Consent and Biobanks , 2005, Journal of Law, Medicine & Ethics.

[33]  Timothy F Cloughesy,et al.  The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. , 2014, Clinical biochemistry.

[34]  Eran Halperin,et al.  Identifying Personal Genomes by Surname Inference , 2013, Science.

[35]  R. Ness Biospecimen “Ownership”: Point , 2007, Cancer Epidemiology Biomarkers & Prevention.

[36]  G. Turashvili,et al.  Nucleic acid quantity and quality from paraffin blocks: defining optimal fixation, processing and DNA/RNA extraction techniques. , 2012, Experimental and molecular pathology.

[37]  B. Kramer,et al.  Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. , 2015, Journal of the National Cancer Institute.

[38]  P. Riegman,et al.  Biobanking residual tissues , 2011, Human Genetics.

[39]  Richard A. Gibbs,et al.  No Longer De-Identified , 2006, Science.

[40]  Lynn G. Dressler Biospecimen “Ownership”: Counterpoint , 2007, Cancer Epidemiology Biomarkers & Prevention.

[41]  Robert Cook-Deegan,et al.  Broad Consent for Research With Biological Samples: Workshop Conclusions , 2015, The American journal of bioethics : AJOB.

[42]  N. Lockhart,et al.  NCI think tank concerning the identifiability of biospecimens and “omic” data , 2013, Genetics in Medicine.

[43]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[44]  D. Wendler Broad versus blanket consent for research with human biological samples. , 2013, The Hastings Center report.